REG - MyHealthChecked PLC - Exercise of Options

MyhealthcheckedAnnouncement

23/12/2024 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241223:nRSW1507Ra&default-theme=true

RNS Number : 1507R  MyHealthChecked PLC  23 December 2024

 

Certain information contained within this Announcement is deemed by the
Company to constitute inside information as stipulated under the UK Market
Abuse Regulation ("MAR") as applied in the United Kingdom. Upon publication of
this Announcement, this information is now considered to be in the public
domain.

 

MyHealthChecked PLC

("MyHealthChecked" or the "Company")

 

Exercise of Options

 

MyHealthChecked PLC (AIM: MHC), the consumer home-testing healthcare
company, announces that the Company has received a request to exercise
options over 30,000 ordinary shares of 1.5p each in the Company. The request
has been satisfied by the allotment on 20 December 2024 of new ordinary shares
issued under the Company's allotment authorities.

 

The New Ordinary Shares rank pari passu in all respects with the Company's
existing Ordinary Shares. An application will be made to the London Stock
Exchange for the 30,000 New Ordinary Shares (the "New Ordinary Shares") to be
admitted to trading on AIM ("Admission"). Admission is expected to occur at
8.00am on or around 31 December 2024.

 

The options, the subject of the request, had an exercise price of 9.5 pence
per share.

 

Admission of shares and total voting rights

 

Following Admission, the total issued share capital of the Company will
consist of 52,035,932 ordinary shares.  As each ordinary share carries the
right to one vote, the total number of voting rights in the Company will be
52,035,932.  This number may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the Company under the
FCA's Disclosure Guidance and Transparency Rules.

 

 

For further information contact:

 

 MyHealthChecked plc                www.myhealthchecked.com (http://www.myhealthchecked.com/)
 Penny McCormick, Chief Executive Officer                                         via Walbrook PR

 SPARK Advisory Partners Limited (NOMAD)                                          Tel: +44 (0)20 3368 3550
 Neil Baldwin / Jade Bayat

 Dowgate Capital Limited (Broker)   Tel: +44 (0)20 3903 7715
 David Poutney / Nicholas Chambers

 Walbrook PR Ltd (Media & IR)       Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com
                                    (mailto:myhealthcheckedplc@walbrookpr.com)
 Paul McManus / Alice Woodings      Mob: +44 (0)7980 541 893 / +44(0)7407 804 654

 

 

About MyHealthChecked PLC (www.myhealthcheckedplc.com
(http://www.myhealthcheckedplc.com/) )

 

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK
healthcare company focused on a range of at-home healthcare and wellness
tests.

 

MyHealthChecked (http://www.myhealthchecked.com/)  is the umbrella brand of a
range of at-home rapid tests, as well as DNA, RNA and blood sample collection
kits which have been created to support customers on their journeys to
wellness. The tests are lateral-flow self-tests, whilst the sample collection
kits enable the collection of blood, urine, nasal or mouth swab samples that
are analysed in partner laboratories for a range of biomarkers. The tests have
been made available online and for over-the-counter purchase.

 

The MyHealthChecked portfolio has been identified as part of a change in
mindset as customers become more familiar with the concept of accessible
healthcare in the growing at home testing kit market with a focus on
accessibility at the right price, led by UK-based experts.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSEAFADALPLFFA